{"id":1441,"date":"2025-09-25T17:03:35","date_gmt":"2025-09-25T20:03:35","guid":{"rendered":"https:\/\/holfik.com\/terapia-genetica-amt-130-trata-doenca-de-huntington\/"},"modified":"2025-09-25T17:03:35","modified_gmt":"2025-09-25T20:03:35","slug":"terapia-genetica-amt-130-trata-doenca-de-huntington","status":"publish","type":"post","link":"https:\/\/holfik.com\/en\/terapia-genetica-amt-130-trata-doenca-de-huntington\/","title":{"rendered":"AMT-130 Gene Therapy Treats Huntington's Disease"},"content":{"rendered":"

Gene Therapy<\/strong> emerges as a new hope in the treatment of Huntington's disease, a devastating neurodegenerative condition.<\/p>\n

In this article, we will explore the recent advances made with AMT-130 therapy, which has demonstrated a significant reduction in disease progression.<\/p>\n

From the positive impact on symptoms observed in 29 patients to the anticipated FDA registration of the drug, we will discuss the results of this clinical trial and how it can change the lives of thousands of people affected by the huntingtin gene mutation in Brazil and around the world.<\/p>\n

AMT-130 Gene Therapy: A Milestone in Huntington's Disease<\/h2>\n

The AMT-130 gene therapy represents a historic milestone in the treatment of Huntington's Disease, achieving a 75% reduction in progression<\/strong> of the disease in just three years.<\/p>\n

This significant advance arose from the clinical study that included 29 patients<\/strong> in the early stages of the disease, undergoing delicate neurological surgery, as reported by search<\/a> carried out by University College London.<\/p>\n

Not only was there a notable decrease in symptoms, but also significant preservation of functional abilities and cognitive improvements, such as memory and reasoning, were observed over the three years of follow-up.<\/p>\n

Witnessing favorable tolerance to the treatment and minimal side effects, expectations are growing regarding the possible registration of the drug with the FDA by 2026, sharpening interest in understanding how this advancement can transform the reality of those with the disease in Brazil and worldwide.<\/p>\n<\/p>\n

Clinical Development of AMT-130<\/h2>\n

The clinical development of AMT-130 represents a significant milestone in the search for effective treatments for Huntington's disease.<\/p>\n

The Phase I\/II clinical trial was designed to evaluate the safety and efficacy of gene therapy in a group of 29 patients with early-stage disease who underwent neurological surgery.<\/p>\n

The promising results revealed a 75% reduction in disease progression over a three-year period, highlighting the transformative potential of this therapeutic approach.<\/p>\n

Profile of the 29 Participants and Surgical Procedure<\/h2>\n

O clinical trial<\/strong> conducted to evaluate the effectiveness of gene therapy AMT-130<\/a> encompassed 29 patients<\/strong> who were in the early stages of Huntington's Disease.<\/p>\n

The importance of targeting patients in the early stages is to slow the progression of the disease before its devastating effects intensify.<\/p>\n

These participants underwent a procedure of neurological surgery<\/strong>, which involved the direct infusion of gene therapy into the brain.<\/p>\n

This procedure is complex, but essential to ensure that the treatment reaches the target areas accurately and effectively.<\/p>\n

The gene infusion method used proved to be revolutionary in providing a significant reduction in disease progression and loss of functional abilities.<\/p>\n

So far, the results have been promising with a 75% reduction in disease progression after three years of treatment.<\/p>\n

This breakthrough represents new hope for many living with the threat of Huntington's disease.<\/p>\n

Continued investigations and improvement of this technique could solidify the future of treatment of genetic diseases<\/u>.<\/p>\n<\/p>\n

Clinical Results at Three Years<\/h2>\n

After three years of treatment with gene therapy AMT-130<\/a>, patients diagnosed with Huntington's disease<\/u> showed significant results<\/strong><\/u> in various aspects of your health.<\/p>\n

The therapy showed a robust reduction in symptoms and improvements in cognitive and functional abilities.<\/p>\n<\/p>\n

Effectiveness<\/strong><\/u>: The progress of the disease slowed noticeably, with a reduction of 75%<\/strong> in the progression of symptoms over the three years of treatment.<\/p>\n

The assessment was measured by the cUHDRS composite scale, bringing hope for effective treatment.<\/p>\n

The positive impact of AMT-130 is visible in the following table:<\/p>\n

\n\n\n\n\n\n\n
Metric<\/th>\nResult<\/th>\n<\/tr>\n<\/thead>\n
Progression<\/td>\n-75%<\/strong><\/td>\n<\/tr>\n
Functional Capabilities<\/td>\n+60%<\/strong><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/blockquote>\n

Cognitive Function<\/strong><\/u>: This treatment also improved the participants' cognitive functions.<\/p>\n

Patients report a significant increase in memory and reasoning, reflected in a reduction of 60%<\/strong> in the loss of functional abilities.<\/p>\n

Furthermore, AMT-130 therapy was well tolerated, with few side effects reported.<\/p>\n

FDA registration is expected in 2026, marking a monumental advance in the treatment of the disease.<\/p>\n<\/p>\n

Safety and Tolerability<\/h2>\n

AMT-130 gene therapy for Huntington's Disease has been shown to be well tolerated<\/strong><\/u> by the patient, presenting few side effects<\/strong> during the clinical trial.<\/p>\n

The most common adverse effects were related to the surgical procedure, but, as reported<\/a>, safety and tolerability were prioritized at all stages.<\/p>\n

According to the results, the incidence of serious complications was minimal.<\/p>\n

For example, side effects included:<\/p>\n